Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs)
Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs)
复制标题
DOI：
10.1046/j.1469-0691.2000.00107.x
复制
发表时间：
2000-09-01
影响因子：
14.2
通讯作者：
Paterson, DL
中科院分区：
文献类型：
--
作者：
Paterson, DL
产超广谱β-内酰胺酶（ESBL）微生物是一个全球性问题。目前还没有随机对照试验来指导最佳治疗。然而，体外研究和观察性研究强烈表明，碳青霉烯类（亚胺培南或美罗培南）应被视为由产ESBL微生物引起的严重感染的首选药物。其他β-内酰胺类抗生素（头孢吡肟、β-内酰胺/β-内酰胺酶抑制剂组合）不适合作为一线治疗。随着喹诺酮类抗生素耐药与产ESBL菌之间的关联频率的增加，这类抗生素对产ESBL菌的作用受到了极大的限制。
Extended-spectrum beta -lactamase (ESBL)-producing organisms are a global problem. No randomized controlled trials have ever been performed to guide optimal treatment. However, in vitro studies and observational studies strongly suggest that carbapenems (imipenem or meropenem) should be regarded as drugs of choice for serious infections due to ESBL-producing organisms. Other beta -lactam antibiotics (cefepime, beta -lactam/beta -lactamase inhibitor combinations) are not suitable as first-line therapy. The increasing frequency of the association between quinolone resistance and ESBL production have greatly limited the role of this class of antibiotic against ESBL producers.